An update on gene therapy in China.

Area of Science:

• Biotechnology and Biomedical Sciences
• Molecular Biology and Genetics

Background:

• Gene therapy has advanced significantly, offering promise for chronic disease treatment.
• China has become a key player in gene therapy development and commercialization.
• The country's pioneering efforts include the first commercialized gene therapy product.

Purpose of the Study:

• To review recent advancements in gene therapy within China.
• To highlight China's contributions to preclinical studies, clinical trials, and product commercialization in gene therapy.

Main Methods:

• Literature review of gene therapy research and development in China.
• Analysis of commercialized gene therapy products and clinical trial data.
• Summary of the landscape of gene therapy companies in China.

Main Results:

• China commercialized the first gene therapy product, Gendicine, in 2003.
• A second product, H-101 (Ocorine), was approved in 2005, establishing China's global recognition.
• Numerous companies are now actively pursuing gene therapy technologies in China.

Conclusions:

• China has demonstrated significant progress and leadership in the field of gene therapy.
• The commercialization of gene therapy products in China has spurred further innovation and company establishment.
• Continued advancements in gene therapy in China are expected to impact global healthcare.